Adrenocortical carcinoma epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(9 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Adrenocortical carcinoma}}
{{Adrenocortical carcinoma}}
{{CMG}}; {{AE}} {{RT}}{{AAM}}
{{CMG}}; {{AE}} {{RT}} {{AAM}} {{MAD}}
==Overview==
==Overview==
Adrenocortical carcinoma is a rare cancer that tends to affect children and young adults.
The [[incidence]] of adrenocortical carcinoma is believed to be 0.72 per million cases per year leading to 0.2% of all cancer deaths in the United States and 0.2 to 0.3 per million children per year worldwide but valid data is lacking. A [[bimodal distribution]] is observed, the first one in [[pediatrics]] and the second one in the fifth to the sixth decade with a predilection for the female gender.
 
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*Adrenocortical carcinoma is a rare [[cancer]], with [[incidence]] of 0.1-0.2 per 100,000 individuals annually.
* The [[incidence]] of adrenocortical carcinoma is 7.2 cases per 100,000 individuals per year leading to 0.2% of all cancer deaths in the United States and 3 cases per 100,000 children per year worldwide but valid data is lacking.<ref name="pmid16551738">{{cite journal| author=Allolio B, Fassnacht M| title=Clinical review: Adrenocortical carcinoma: clinical update. | journal=J Clin Endocrinol Metab | year= 2006 | volume= 91 | issue= 6 | pages= 2027-37 | pmid=16551738 | doi=10.1210/jc.2005-2639 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16551738  }}</ref>
===Age===
 
*Adrenocortical carcinoma has a [[bimodal distribution]] by age, with cases clustering in children under 6, and in adults 30-40 years old.<ref name="DeVita"/>
=== Age ===
* A [[bimodal distribution]] was observed, the first one in pediatrics and the second one in the fifth to the sixth decade.<ref name="pmid19500769">{{cite journal| author=Fassnacht M, Allolio B| title=Clinical management of adrenocortical carcinoma. | journal=Best Pract Res Clin Endocrinol Metab | year= 2009 | volume= 23 | issue= 2 | pages= 273-89 | pmid=19500769 | doi=10.1016/j.beem.2008.10.008 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19500769  }}</ref>
 
=== Gender ===
* There is a predilection for the female gender.<ref name="pmid2325710">{{cite journal| author=Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X et al.| title=Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. | journal=N Engl J Med | year= 1990 | volume= 322 | issue= 17 | pages= 1195-201 | pmid=2325710 | doi=10.1056/NEJM199004263221705 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2325710  }}</ref>
* Girls are also more commonly affected than boys with a ratio of 1.6:1.<ref name="pmid14990639">{{cite journal| author=Michalkiewicz E, Sandrini R, Figueiredo B, Miranda EC, Caran E, Oliveira-Filho AG et al.| title=Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. | journal=J Clin Oncol | year= 2004 | volume= 22 | issue= 5 | pages= 838-45 | pmid=14990639 | doi=10.1200/JCO.2004.08.085 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14990639  }}</ref>


==References==
==References==

Latest revision as of 15:46, 17 October 2017

Adrenocortical carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adrenocortical carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

MRI

CT

Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation Therapy

Primary prevention

Secondary prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Study

Case #1

Adrenocortical carcinoma epidemiology and demographics On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adrenocortical carcinoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adrenocortical carcinoma epidemiology and demographics

CDC on Adrenocortical carcinoma epidemiology and demographics

Adrenocortical carcinoma epidemiology and demographics in the news

Blogs on Adrenocortical carcinoma epidemiology and demographics

Hospitals Treating Adrenocortical carcinoma

Risk calculators and risk factors for Adrenocortical carcinoma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Ahmad Al Maradni, M.D. [3] Mohammed Abdelwahed M.D[4]

Overview

The incidence of adrenocortical carcinoma is believed to be 0.72 per million cases per year leading to 0.2% of all cancer deaths in the United States and 0.2 to 0.3 per million children per year worldwide but valid data is lacking. A bimodal distribution is observed, the first one in pediatrics and the second one in the fifth to the sixth decade with a predilection for the female gender.

Epidemiology and Demographics

Incidence

  • The incidence of adrenocortical carcinoma is 7.2 cases per 100,000 individuals per year leading to 0.2% of all cancer deaths in the United States and 3 cases per 100,000 children per year worldwide but valid data is lacking.[1]

Age

  • A bimodal distribution was observed, the first one in pediatrics and the second one in the fifth to the sixth decade.[2]

Gender

  • There is a predilection for the female gender.[3]
  • Girls are also more commonly affected than boys with a ratio of 1.6:1.[4]

References

  1. Allolio B, Fassnacht M (2006). "Clinical review: Adrenocortical carcinoma: clinical update". J Clin Endocrinol Metab. 91 (6): 2027–37. doi:10.1210/jc.2005-2639. PMID 16551738.
  2. Fassnacht M, Allolio B (2009). "Clinical management of adrenocortical carcinoma". Best Pract Res Clin Endocrinol Metab. 23 (2): 273–89. doi:10.1016/j.beem.2008.10.008. PMID 19500769.
  3. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X; et al. (1990). "Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy". N Engl J Med. 322 (17): 1195–201. doi:10.1056/NEJM199004263221705. PMID 2325710.
  4. Michalkiewicz E, Sandrini R, Figueiredo B, Miranda EC, Caran E, Oliveira-Filho AG; et al. (2004). "Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry". J Clin Oncol. 22 (5): 838–45. doi:10.1200/JCO.2004.08.085. PMID 14990639.

Template:WikiDoc Sources